Skip to main content
profile image
Selected Works of John M. Pagel, MD, PhD
Article
Long-term efficacy and safety with ibrutinib (ibr) in previously treated chronic lymphocytic leukemia (CLL): Up to four years follow-up of the RESONATE study.
Journal of Clinical Oncology (2017)
  • John C. Byrd, Ohio State University
  • Peter Hillmen, Leeds Teaching Hospitals NHS Trust
  • Susan Mary O'Brien, University of Texas MD Anderson Cancer Center
  • Jacqueline Claudia Barrientos, Hofstra University
  • Nishitha M. Reddy, Vanderbilt University Medical Center
  • Steven Coutre, Stanford University
  • Constantine S. Tam, St. Vincent's Health System
  • Stephen P. Mulligan, Royal North Shore Hospital
  • Ulrich Jäger, Medical University of Vienna
  • Paul M. Barr, University of Rochester
  • Richard R. Furman, Cornell University
  • Thomas J. Kipps, University of California, San Diego
  • Patrick Thornton, Beaumont Hospital
  • John M. Pagel, Cancer Institute
  • Jan Andreas Burger, University of Texas MD Anderson Cancer Center
  • Jeffrey Alan Jones, University of California, San Diego
  • Sandra Dai
  • Remus N. Vezan
  • Danelle Frances James, University of California, San Diego
  • Jennifer R. Brown, Harvard University
Link
Disciplines
Publication Date
May 30, 2017
Citation Information
John C. Byrd, Peter Hillmen, Susan Mary O'Brien, Jacqueline Claudia Barrientos, et al.. "Long-term efficacy and safety with ibrutinib (ibr) in previously treated chronic lymphocytic leukemia (CLL): Up to four years follow-up of the RESONATE study." Journal of Clinical Oncology (2017)
Available at: http://works.bepress.com/john-pagel/12/